These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6234505)

  • 1. Effects of megavitamin therapy on children with attention deficit disorders.
    Haslam RH; Dalby JT; Rademaker AW
    Pediatrics; 1984 Jul; 74(1):103-11. PubMed ID: 6234505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Megavitamins for minimal brain dysfunction. A placebo-controlled study.
    Arnold LE; Christopher J; Huestis RD; Smeltzer DJ
    JAMA; 1978 Dec; 240(24):2642-3. PubMed ID: 712981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a role for megavitamin therapy in the treatment of attention deficit hyperactivity disorder?
    Haslam RH
    Adv Neurol; 1992; 58():303-10. PubMed ID: 1414636
    [No Abstract]   [Full Text] [Related]  

  • 6. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.
    Nikles CJ; Mitchell GK; Del Mar CB; Clavarino A; McNairn N
    Pediatrics; 2006 Jun; 117(6):2040-6. PubMed ID: 16740846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder.
    Voigt RG; Llorente AM; Jensen CL; Fraley JK; Berretta MC; Heird WC
    J Pediatr; 2001 Aug; 139(2):189-96. PubMed ID: 11487742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylphenidate dosing: twice daily versus three times daily.
    Stein MA; Blondis TA; Schnitzler ER; O'Brien T; Fishkin J; Blackwell B; Szumowski E; Roizen NJ
    Pediatrics; 1996 Oct; 98(4 Pt 1):748-56. PubMed ID: 8885956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial.
    Akhondzadeh S; Tavakolian R; Davari-Ashtiani R; Arabgol F; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):841-5. PubMed ID: 12921918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is a significant response in drug studies of attention-deficit/hyperactivity disorder: statistical significance is necessary, but is it sufficient?
    Sangal RB; Sangal JM
    Psychopharmacol Bull; 2003; 37(2):50-8. PubMed ID: 14566214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bach flower remedies used for attention deficit hyperactivity disorder in children--a prospective double blind controlled study.
    Pintov S; Hochman M; Livne A; Heyman E; Lahat E
    Eur J Paediatr Neurol; 2005; 9(6):395-8. PubMed ID: 16257245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study.
    Hirayama S; Hamazaki T; Terasawa K
    Eur J Clin Nutr; 2004 Mar; 58(3):467-73. PubMed ID: 14985685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.